Our mission is to create a new category of therapeutics that resolve the damage caused by devastating diseases. Our core innovation is the discovery of a global master regulator, the Innate Repair Receptors (IRR), that produces cellular and tissue repair in various disease states. Our lead compound in clinical development, Cibinetide, is focused on addressing unmet needs in neuroscience and diabetes complications. We have developed an extensive peptide library of IRR activators, with in-vivo proof of concept efficacy for 10 unique compounds and an extensive catalogue of scientific literature in collaboration with leading academic researchers around the globe.
NEUROSCIENCE
Cibinetide, our lead product, is preparing for phase 3 initiation based upon prior studies which demonstrate regeneration of nerve fibers, reduction in pain, and functional improvements.
DIABETES COMPLICATIONS
Poised to pursue IND application and phase 2 trials in four different complications of diabetes including diabetic liver disease (NASH), diabetic kidney disease, heart failure, and diabetic wound healing.
OUR FOCUS
Mr Young brings more than 25 years of pharmaceutical and biotechnology commercialization experience to Araim including senior executive leadership roles in large pharmaceutical firms and earlier stage startups, and as a successful entrepreneur. He has extensive experience working for and with leading companies and products in the fields of diabetes and cardiovascular disease. At Araim, he is responsible for defining and implementing our strategic roadmap to ensure that our innovation reaches the patient through appropriate partnerships.
Dr Breedveld brings more than 40 years of achievements in clinical research, service to patients, and executive leadership within immunology, rheumatology, and translational medicine. He served as the Head of Leiden University Medical Center in the Netherlands and as President of the European League Against Rheumatism (EULAR), and has also served 10 years at the Drug Evaluation Committee of the Netherlands. In addition, Dr Breedveld has authored more than 900 peer-reviewed scientific papers and received multiple awards, including Honorary Member of EULAR and Master of the American College of Rheumatology (ACR).
Dr Bajorunas brings nearly 25 years of pharmaceutical and biotechnology developmental experience in both operational and executive leadership roles. She has extensive experience leading global product development, including drug (Rx and OTC), device, and dietary supplement/medical food, across multiple disease states and therapeutic areas. She has led development of products across a range of delivery technologies (oral, transdermal, intravaginal, subcutaneous, and inhalation delivery), ensured their regulatory approval (US, EU, and Japan), and optimized them across the entire life cycle, through phase 4. At Araim, she is responsible for all ARA 290 clinical-stage strategic, developmental, and regulatory activities. 
Dr Rita Kirk joined the Araim team in 2012 as Project Manager, with 14 years of research in cell signaling, cardiovascular disease, and muscle biology and 10 years of pharmaceutical experience. At Araim, she directs the preclinical safety programs, and manages extramural funding, research collaborations, contract research organizations, and consultants. She is responsible for overseeing the management of the clinical and regulatory programs, as well as the manufacturing projects within the company. Dr Kirk received her PhD from New York Medical College and a BS from SUNY Albany. She did her postdoctoral work at Mount Sinai School of Medicine in New York City.
Mr Harrington brings 18 years of extensive experience in biotechnology and pharmaceutical commercialization and marketing strategies to Araim. Mr Harrington’s broad therapeutic experience and proven track record of success in launching and marketing products in neurology, pain, diabetes, rheumatology, and psychiatry will be instumental in the development of the commercialization strategy for ARA 290.
